Patents Examined by Theodore R West
  • Composition for treating cancer stem cells
    Patent number: 10420814
    Abstract: The present invention relates to a composition for effectively treating cancer stem cells, and more specifically to a composition for treating cancer stem cells, which contains a glucose uptake inhibitor, a biguanide-based compound, and a calcium pump inhibitor. The composition of the present invention can be used as an agent of treating cancer stem cells by effectively inducing apoptosis of the cancer stem cells. Accordingly, the composition of the present invention can be used as a pharmaceutical composition capable of effectively treating various cancer stem cells to effectively inhibiting cancer recurrence and/or metastasis.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: September 24, 2019
    Assignee: Haimbio Co., Ltd.
    Inventors: Jae Ho Cheong, Eun Sung Park, Ki Cheong Park
  • Methods of treating developmental disorders and/or seizure disorders with etifoxine
    Patent number: 10420773
    Abstract: Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder and/or seizure disorder.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: September 24, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Neurochemical wellness program
    Patent number: 10413563
    Abstract: A novel process for improving neurochemical health includes a multi-day treatment program including intravenous delivery of nicotinamide adenine dinucleotide (NAD) to at least partially restore a patient's brain to a desired chemical balance. Intravenous delivery of NAD is synergistically combined with delivery of selected amino acids and, depending on the ailment being treated, a combination of ozone, testosterone, glutathione, Myers cocktail or other specified compounds.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: September 17, 2019
    Assignee: Emerald Neuro-Recover, LLC
    Inventor: Joseph W. Pappas
  • Methods of inhibiting cataracts and presbyopia
    Patent number: 10413529
    Abstract: Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a ?-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: September 17, 2019
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Murugappan Muthukumar, Benjamin Mohr
  • Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders using an inhibitor of Akt kinase
    Patent number: 10413542
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 17, 2019
    Assignees: Buck Institute for Research on Aging, Unity Biotechnology, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • Compositions and methods for treating neoplasia, inflammatory disease and other disorders
    Patent number: 10407441
    Abstract: The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: September 10, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James Elliott Bradner, Jun Qi
  • 3,6-disubstituted xanthylium salts
    Patent number: 10399955
    Abstract: Described are a compound of formula (II) or (III): The compounds are effective in the treatment of disease, including a tauopathy condition or a disease of tau protein aggregation.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 3, 2019
    Assignee: WISTA LABORATORIES LTD.
    Inventors: Scott Clunas, John Mervyn David Storey, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Claude Michel Wischik
  • Use of alpha-hydroxy carbonyl compounds as reducing agents
    Patent number: 10398676
    Abstract: There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 3, 2019
    Assignee: MORVUS TECHNOLOGY LIMITED
    Inventor: Richard J. Knox
  • Pharmaceutical tetracycline composition for dermatological use
    Patent number: 10391108
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 27, 2019
    Assignee: BioPharmX, Inc.
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Biodegradable lipids for the delivery of active agents
    Patent number: 10369226
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: August 6, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Method of reducing scarring
    Patent number: 10369118
    Abstract: A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 6, 2019
    Assignee: Cole Research & Design, LLC
    Inventor: Jeptha N. Cole
  • Methods of treating basal cell carcinoma and glioblastoma
    Patent number: 10369170
    Abstract: Provided herein are methods of treating basal cell carcinoma or glioblastoma by administering coal tar or a coal tar product to a patient with basal cell carcinoma or glioblastoma. The coal tar or coal tar product may be administered as a standalone therapy or in combination with other treatments for basal cell carcinoma or glioblastoma.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: August 6, 2019
    Inventor: Carol J. Buck
  • Topical compositions comprising retinoids and low irritation polymeric cleansing agents
    Patent number: 10350153
    Abstract: Topical compositions comprising a retinoid, a low irritation polymeric cleansing agent and a cosmetically-acceptable topical carrier are provided. Such compositions provide improved retinoid activity for treating for example signs of skin aging, acne, or rosacea.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: July 16, 2019
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Michael Chang, Michael James Fevola, Simarna Kaur, Michael D. Southall, Ali Fassih
  • Use of selected anticholinergic zwitterions
    Patent number: 10335367
    Abstract: Selected anticholinergic zwittehons are administered to slow the progression of myopia in children and to treat myopia generally.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 2, 2019
    Assignee: BODOR LABORATORIES, INC.
    Inventor: Nicholas S. Bodor
  • Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
    Patent number: 10328058
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 25, 2019
    Assignees: Mayo Foundation for Medical Education and Research, Unity Biotechnology, Inc., Buck Institute for Research on Aging
    Inventors: Darren J. Baker, Marco Demaria, Albert Davalos, Bennett G. Childs, Jan M. A. van Deursen, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi
  • Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells
    Patent number: 10328073
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 25, 2019
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Compounds and methods for inhibiting Cif virulence factor
    Patent number: 10322118
    Abstract: The present invention provides a screening assay for identifying inhibitors of Pseudomonas aeruginosa CFTR Inhibitory Factor as well as compositions and methods for ameliorating or treating a respiratory disease such as cystic fibrosis or secondary infection thereof.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: June 18, 2019
    Assignees: TRUSTEES OF DARTMOUTH COLLEGE, THE REGENTS OF TE UNIVERSITY OF CALIFORNIA
    Inventors: Dean R. Madden, Christopher D. Bahl, Bruce D. Hammock, Christophe Morisseau
  • Pharmaceutical formulations of ecteinascidin compounds
    Patent number: 10322183
    Abstract: Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 18, 2019
    Assignee: PHARMA MAR, S.A., SOCIEDAD UNIPERSONAL
    Inventors: Jacob Hendrik Beijnen, Bastiaan Nuijen, Pilar Calvo Salve, Maria Tobio Barreira
  • Pyridinyl and fused pyridinyl triazolone derivatives
    Patent number: 10307414
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • Methods, compounds, and compositions for the treatment of angiotensin-related diseases
    Patent number: 10301298
    Abstract: Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 28, 2019
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Nicos A. Petasis, Kathleen E. Rodgers, Stan G. Louie, Gere S. DiZerega, Kevin J. Gaffney